Pregnancy

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

 Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment…

12 months ago

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life…

1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second…

1 year ago

Michigan Department of Health and Human Services Expands Philips Avent Pregnancy+ Program; Nearly 80% of Users Say App Has Helped Them Learn More About Locally Available Maternal Health Resources

Program reaches 12,000 Medicaid-eligible families Michigan-specific content viewed over 850,000 times in the first year Michigan expanding access to premium…

1 year ago

MATTER opens applications for accelerator focused on reducing maternal mortality in the U.S.

Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support…

1 year ago

Expert Panel Provides Updated Data for Epilepsy and Pregnancy

BOSTON, MA / ACCESSWIRE / December 5, 2023 / The Epilepsy & Pregnancy Medical Consortium (EPMC), an expert panel of…

1 year ago

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE)…

1 year ago

AstraZeneca advances scientific leadership in hematology at ASH 2023

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of…

1 year ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration…

1 year ago